Top Alliance Of 2016: Cast Your Vote!
It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
In Vivo's Top Alliance Of 2016 – The Nominees Are:
Synthetic Bio Tie-Up: Synologic received big pharma validation of its technology in early February, signing its first-ever partnership, a multiyear collaboration with AbbVie to develop "synthetic biotic" therapies for Crohn's disease and ulcerative colitis. [See Deal]
Cigna Pays If PCSK9s Perform: In May, Cigna signed value-based contracts with Amgen and Sanofi/Regeneron for their cholesterol-lowering drugs Repatha and Praluent. The drugmakers will discount the products more steeply if LDL levels don't drop.
AZ Drops Assets: In October, AstraZeneca completed five out-licensing deals cumulatively worth more than $1 billion, the busiest month by far in its year-long purge of non-core assets. [See Deal][See Deal][See Deal][See Deal][See Deal]
Bayer Buys Into Gene Editing: In August, Bayer and CRISPR Therapeutics unveiled their $335 million joint venture Casebia Therapeutics, which will use CRISPR's gene editing technology to develop drugs for blood disorders, blindness and congenital heart disease.
Coming Up Next In IVDOTY16: Top Financing And Top M&A